Canna~Fangled Abstracts

Phytomedicine for neurodegenerative diseases: The road ahead

By April 10, 2024April 11th, 2024No Comments

Review

doi: 10.1002/ptr.8192.

Online ahead of print.
Affiliations 

Abstract

Neurodegenerative disorders (NDs) are among the most common causes of death across the globe. NDs are characterized by progressive damage to CNS neurons, leading to defects in specific brain functions such as memory, cognition, and movement. The most common NDs are Parkinson’s, Alzheimer’s, Huntington’s, and amyotrophic lateral sclerosis (ALS). Despite extensive research, no therapeutics or medications against NDs have been proven to be effective. The current treatment of NDs involving symptom-based targeting of the disease pathogenesis has certain limitations, such as drug resistance, adverse side effects, poor blood-brain barrier permeability, and poor bioavailability of drugs. Some studies have shown that plant-derived natural compounds hold tremendous promise for treating and preventing NDs. Therefore, the primary objective of this review article is to critically analyze the properties and potency of some of the most studied phytomedicines, such as quercetin, curcumin, epigallocatechin gallate (EGCG), apigenin, and cannabinoids, and highlight their advantages and limitations for developing next-generation alternative treatments against NDs. Further extensive research on pre-clinical and clinical studies for developing plant-based drugs against NDs from bench to bedside is warranted.

Keywords: clinical studies, neurodegenerative disorder, next‐generation drug, phytomedicines

PubMed Disclaimer

References

REFERENCES

    1. Ader, P., Wessmann, A., & Wolffram, S. (2000). Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radical Biology Medicine, 28(7), 1056–1067.
    1. Ahmad, S., Khan, A., Tabassum, S., Batool, Z., Ahmed, S. B., Khaliq, S., Ahuja, A. K., Hashmi, A., Rafiq, H., & Haider, S. (2022). Co‐administration of saffron and chamomile give additive effects of antidiabetic and antioxidant activity with in vivo augmentation of brain BDNF, acetylcholine levels and cognitive functions in streptozotocininduced diabetic rats. Current Psychopharmacology, 11(1), 56–69.
    1. Akhtar, A., Andleeb, A., Waris, T. S., Bazzar, M., Moradi, A.‐R., Awan, N. R., & Yar, M. (2021). Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. Journal of Controlled Release, 330, 1152–1167.
    1. Alam, M., Ali, S., Ashraf, G. M., Bilgrami, A. L., Yadav, D. K., & Hassan, M. I. (2022). Epigallocatechin 3‐gallate: From green tea to cancer therapeutics. Food Chemistry, 379, 132135.
    1. Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021). From combinations to multitarget‐directed ligands: A continuum in Alzheimer’s disease polypharmacology. Medicinal Research Reviews, 41(5), 2606–2633.

Publication types

Leave a Reply